Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | RAB9A | P51151 | 4/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.71 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.61 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.61 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95599 | 0.90 | NPC1 (0.75) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL4254150 | 0.86 | MEN1 (0.80) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL2982452 | 0.85 | MEN1 (0.77) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL4254970 | 0.83 | RAB9A (0.75) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL667807 | 0.83 | BCAT2 (0.77) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL3645013 | 0.83 | MEN1 (0.74) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL95888 | 0.81 | NPC1 (0.65) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL94726 | 0.81 | NPC1 (0.65) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL12190100 | 0.81 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL6928173 | 0.81 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | MEN1 4686/4885KMT2A 1470/4885NPC1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.